重组人干扰素γ联合紫杉醇+卡铂化疗方案对卵巢癌患者T淋巴细胞亚群水平的影响  

Effect of Recombinant Human Interferon Gamma Combined with Taxol and Carboplatin Chemotherapy on T Lymphocyte Subsets in Patients with Ovarian Cancer

作　　者：张玉洁[1] 莫琼梅 ZHANG Yujie;MO Qiongmei(Wenchang Peopte's Hospital,Wenchang,Hainan,China 571300)

机构地区：[1]海南省文昌市人民医院,海南文昌771340

出　　处：《中国药业》2021年第5期41-44,共4页China Pharmaceuticals

基　　金：海南省自然科学基金面上项目[817362]。

摘　　要：目的探讨重组人干扰素γ联合紫杉醇+卡铂(TC)化疗方案治疗卵巢癌的疗效,以及对T淋巴细胞亚群水平的影响。方法选取医院2017年6月至2018年6月收治的卵巢癌患者91例,按随机数字表法分为研究组(46例)和对照组(45例)。两组患者均予TC化疗方案,研究组加用重组人干扰素γ。两组均以21 d为1个治疗周期,连续化疗3个周期。结果治疗后,研究组患者的客观缓解率(ORR)、疾病控制率(DCR)分别为63.04%和76.09%均显著高于对照组的42.22%和55.56%(P<0.05);研究组患者的T淋巴细胞亚群(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))水平均显著高于对照组,CD8^(+)细胞阳性率显著低于对照组(P<0.05);研究组卵巢癌相关蛋白[存活素、切除修复交叉互补基因蛋白1(ERCC1)、波形蛋白]的水平均显著低于对照组(P<0.05);随访2年,研究组无进展生存期(PFS)显著长于对照组,1年及2年生存率均显著高于对照组(P<0.05);研究组与对照组不良反应发生率相当(23.91%比15.56%,P>0.05)。结论重组人干扰素γ联合TC化疗方案治疗卵巢癌疗效显著,可提升患者的免疫功能,降低卵巢癌相关蛋白水平,延长生存期,且安全性良好。Objective To investigate the effect of recombinant human interferon gamma(rhIFN-γ)combined with taxol and carboplatin(TC)in the treatment of patients with ovarian cancer and its effect on T lymphocyte subsets.Methods Totally 91 patients with ovarian cancer admitted to our hospital from June 2017 to June 2018 were selected and divided into the study group(46 cases)and the control group(45 cases)according to the random number table method.The patients in the two groups were treated with TC chemotherapy,on this basis,the patients in the study group were treated with rhIFN-γ.Both groups were continuously treated with chemotherapy for three cycles with 21 d as a cycle.Results After treatment,the objective remission rate(ORR)and disease control rate(DCR)of the study group were 63.04%and 76.09%,which were significantly higher than 42.22%and 55.56%of the control group(P<0.05).The levels of T lymphocyte subsets(CD3+,CD4+,CD4+/CD8+)in the study group were significantly higher than those in the control group,while the positive rate of CD8+cell in the study group was significantly lower than that in the control group(P<0.05).The levels of ovarian cancer related protein[survivin,excision repair cross-complementing gene-1(ERCC1)and vimentin]in the study group were significantly lower than those in the control group(P<0.05).During the 2-year follow-up,the progression free survival(PFS)of the study group were significantly longer than that of the control group,the 1-year survival rate and 2-year survival rate of the study group were significantly higher than those of the control group(P<0.05).The incidence of adverse reactions in the study group was similar to that in the control group(23.91%vs.15.56%,P>0.05).Conclusion rhIFN-γcombined with TC chemotherapy is effective and safe in the treatment of ovarian cancer,which can improve the immune function of patients,reduce the level of ovarian cancer related protein,prolong the life cycle.

关 键 词：卵巢癌 卡铂 紫杉醇 重组人干扰素Γ 临床疗效 T淋巴细胞亚群 

分 类 号：R969.2[医药卫生—药理学] R979.2[医药卫生—药学]